GWP
TNXP icon

Gen-Wealth Partners’s Tonix Pharmaceuticals TNXP Stock Holding History

Gen-Wealth Partners’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.8K Hold
533
– – ﹤0.01% 578
2026
Q1 		$7.33K Hold
533
– – ﹤0.01% 566
2025
Q4 		$8.32K Hold
533
– – ﹤0.01% 532
2025
Q3 		$12.9K Buy
+533
New +$19.8K ﹤0.01% 499

Other funds holding TNXP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
II
Ishara Investments Los Angeles, California $136M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Gen-Wealth Partners's TNXP Position: Q2 2026 in Review

Gen-Wealth Partners held its Tonix Pharmaceuticals (TNXP) position steady in Q2 2026 at 533 shares worth $6.8K. The position accounts for ﹤0.01% of the portfolio, ranked #578.

Gen-Wealth Partners first reported a position in TNXP in Q3 2025 and has held it in 4 quarters since. The position peaked at $12.9K in Q3 2025. 103 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

  • Gen-Wealth Partners held 533 shares of Tonix Pharmaceuticals worth $6.8K as of Q2 2026.
  • Gen-Wealth Partners left its Tonix Pharmaceuticals share count unchanged in Q2 2026.
  • Tonix Pharmaceuticals made up ﹤0.01% of Gen-Wealth Partners's portfolio in Q2 2026, its #578 holding.
  • Gen-Wealth Partners first reported a position in Tonix Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Gen-Wealth Partners's Tonix Pharmaceuticals position peaked at $12.9K in Q3 2025.
  • 103 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on Gen-Wealth Partners's 13F filing for Q2 2026, filed 10 Aug 2026.